Pfizer Appoints Cecile Guegan as Permanent CFO and Executive Vice President

Executive Appointment Overview

On November 3, 2026, Pfizer Inc. reported under Item 5.02 of Form 8-K that its Board of Directors unanimously elected Cecile Guegan to serve as Chief Financial Officer and Executive Vice President of the Company, effective November 1, 2026.

Ms. Guegan, 55, had previously been serving as Interim Chief Financial Officer since August 16, 2026.

Professional Background

• Pfizer Tenure & Experience: More than 25 years of global finance leadership within the pharmaceutical sector. She joined Pfizer in 2009 in connection with the Wyeth acquisition, where she was CFO supporting Asia Pacific and EMEA/Canada operations.
• Recent Roles: Prior to becoming Interim CFO, Ms. Guegan served as Senior Vice President of Finance for Pfizer's Global Biopharmaceuticals business (2022–2026) and Vice President, Finance, Research & Development and Business Office (2020–2022).
• Education: Holds a Master’s degree in Management (Audit and Finance) from the Graduate School of Management of Brest, France, and a French DECF accounting degree.

Approved Compensation Structure

In connection with her appointment, the Compensation Committee approved the following compensation package as of the Effective Date:

• Annual Base Salary: $1,300,000
• Target Annual Cash Incentive: 100% of base salary ($1,300,000), calculated on salary paid during the year.

Market & Strategic Significance

The transition from interim to permanent CFO concludes leadership uncertainty in the finance seat. Given her long-standing internal tenure across R&D, biopharma, and enterprise integration, the appointment provides operational continuity as Pfizer focuses on capital discipline and commercial execution.